Our team consist of hematologists, key opinion leaders from hematology society, AI engineers, data scientist, marketers, serial entrepreneurs and pharmaceutical executives.
Goals and Plan
Our vision is to create tools to support physician for every types of blood cancer treatment and at each critical clinical decision point. We plan to spin-off from the universities by 2020 and prepare for our first residual leukemia cell detection model FDA SaMD submission.
Our AHEAD models will be protected by patent and trade secrets in our future startup operation.
There are 1.5 millions of new diagnosed blood cancer patients each year and the estimated flow cytometry interpretation demand is around 20 millions interpretation.